With the US Inflation Reduction Act threatening a major shake-up in drug pricing from 2023 onwards, and with the progress of increasing numbers of costly advanced therapeutics onto the market, one thing is sure: pricing and reimbursement will remain critical issues this year.
Scrip Asks… What Does 2023 Hold For Biopharma? Part 4: Pricing And Reimbursement
Advanced Therapies And IRA Transform Landscape
Biopharma executives see value-based pricing as an increasingly important topic for the sector in 2023, while the US Inflation Reduction Act will have a major impact on portfolio strategies.
More from Scrip Asks
More from Scrip
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.